614 completed, 151 terminated, 76 unknown, 62 active not recruiting. 625 Phase 2, 204 Phase 1, 158 Phase 3, 34 Not applicable, 30 Phase 4.
Follow Avastin: new trials by email Literature Review of Avastin trials Research Report on Avastin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab - Colo-rectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | CytomX Therapeutics | 368 | 2026-12-01 | 2026-10-28 |
| Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC) | Not yet recruiting | Assiut University | 294 | 2026-11-01 | 2026-10-29 | |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-10-29 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases Bevacizumab, Ipilimumab, Nivolumab - Melanoma Brain Metastases | Phase 1 / Phase 2 | Recruiting | Melanoma and Skin Cancer Trials Limited | 46 | 2026-08-31 | 2026-10-13 |
| Sitagliptin in Recurrent/Progressive Grade 4 Glioma Sitagliptin, Bevacizumab - Glioma, Glioblastoma | Phase 1 | Recruiting | Kailin Yang, MD, PhD | 45 | 2026-06-11 | 2026-06-17 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC | Phase 2 | Recruiting | Oncolytics Biotech | 60 | 2026-04-30 | 2026-10-27 |
| An Observational Study to Learn About the Medicine - BEVACIZUMAB BS [Pfizer] in Colorectal Cancer Patients From Japan. Bevacizumab-Pfizer Biosimilar, Avastin - Colorectal Cancer | Completed | Pfizer | 1000 | 2026-04-20 | 2026-06-03 | |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) Sacituzumab tirumotecan, Bevacizumab, Rescue Medications - Ovarian Neoplasms, Ovarian Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 900 | 2026-02-16 | 2026-10-13 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer Inavolisib, Bevacizumab, FOLFOX - Colorectal Cancer | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-02-01 | 2026-02-09 | |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
| A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors PF-08032562, Fulvestrant, Cetuximab - Advanced Breast Cancer, Metastatic Breast Cancer (HR+/ HER2-) | Phase 1 | Recruiting | Pfizer | 260 | 2025-12-23 | 2026-07-22 |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer PF-08634404, Bevacizumab, Chemotherapy - Intestinal Neoplasms, Gastrointestinal Neoplasms | Phase 3 | Recruiting | Pfizer | 800 | 2025-12-11 | 2026-10-08 |
| Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer Bevacizumab, Biospecimen Collection, Computed Tomography - Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-10-31 | 2025-06-03 | |
| - IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases Fruquintinib, Tislelizumab, Trifluridine/tipiracil - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 140 | 2025-10-27 | 2025-12-12 |
| A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial Chemotherapy, Computed Tomography, Internet-Based Intervention - Glioma, Recurrent Glioma | Not applicable | Recruiting | Mayo Clinic | 202 | 2025-09-12 | 2026-08-10 |
| Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis Intra-articular Bevacizumab - Hemophilia, Chronic Synovitis | Not applicable | Completed | Khyber Medical University Peshawar | 18 | 2025-09-09 | 2026-06-25 |
| BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients Trifluridine/tipiracil, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 162 | 2025-09-01 | 2025-07-17 |
Showing 20 of 1004. Sign in to see all of them.
Colorectal Neoplasms (145) · Breast Neoplasms (94) · Glioblastoma (92) · Carcinoma, Non-Small-Cell Lung (83) · Ovarian Neoplasms (82) · Brain Neoplasms (53) · Neoplasms (52) · Fallopian Tube Neoplasms (49) · Rectal Neoplasms (46) · Glioma (45) · Neoplasm Metastasis (45) · Carcinoma, Renal Cell (43) · Colonic Neoplasms (42) · Lung Neoplasms (37) · Carcinoma, Hepatocellular (36)
National Cancer Institute (NCI) (142) · Hoffmann-La Roche (74) · M.D. Anderson Cancer Center (58) · SCRI Development Innovations, LLC (26) · Dana-Farber Cancer Institute (18) · Duke University (16) · Hellenic Oncology Research Group (13) · Genentech, Inc. (12) · Massachusetts General Hospital (12) · Sun Yat-sen University (11) · Pfizer (10) · Amgen (8) · Northwestern University (8) · Mayo Clinic (7) · AstraZeneca (6)
United States (657) · Spain (88) · China (87) · Canada (80) · France (80) · Italy (71) · Germany (58) · South Korea (51) · United Kingdom (51) · Japan (45) · Australia (44) · Netherlands (42) · Belgium (41) · Taiwan (41) · Austria (36)
Annick Desjardins, MD, FRCPC (6) · Dimitris Mavrudis, MD (5) · John D. Hainsworth, MD (5) · Sofia Agelaki, MD (5) · Apostolia M. Tsimberidou, MD, PhD (4) · Hedy Kindler (4) · Norman Wolmark, MD (4) · Apostolia M. Tsimberidou, MD, PHD (3) · David A. Reardon, MD (3)
PMID 37185961, PMID 34616010, PMID 32411431, PMID 37146227, PMID 39777725, PMID 21383283, PMID 21941283, PMID 23168366, PMID 29522361, PMID 31139483, PMID 31276981, PMID 32427087, PMID 34028627, PMID 39890560, PMID 12636887, PMID 12648575, PMID 15169803, PMID 15215160, PMID 15313917, PMID 15681523, PMID 15755984, PMID 16107633, PMID 16111068, PMID 16172161, PMID 16172168, PMID 16204015, PMID 16583638, PMID 16790519, PMID 16797681, PMID 16940982, PMID 17016557, PMID 17167137, PMID 17647245, PMID 17698196, PMID 17765429, PMID 18160686, PMID 18185135, PMID 18272024, PMID 18316792, PMID 18443902, PMID 18561992, PMID 18565886, PMID 18692246, PMID 18710781, PMID 18824714, PMID 18854571, PMID 18854726, PMID 19097774, PMID 19192962, PMID 19201650
U10CA180868 (21), U10CA027469 (19), U10CA021115 (15), U10CA180820 (12), 2023 (11), U10CA032102 (11), U10CA031946 (10), 2009 (9), P30CA015083 (9), U10CA021661 (8), U10CA180821 (8), 2014 (7), N01CM62201 (7), N01CM62204 (6), P30CA033572 (6)